tailieunhanh - Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort

With the introduction of DNA-damaging therapies into standard of care cancer treatment, there is a growing need for predictive diagnostics assessing homologous recombination deficiency (HRD) status across tumor types. Following the strong clinical evidence for the utility of DNA-sequencing-based HRD testing in ovarian cancer, and growing evidence in breast cancer, we present analytical validation of the Tempus HRD-DNA test. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN